and vision fields. On January 13, Johnson & Johnson (NYSE:JNJ) announced the $14.6 billion acquisition of neurological drugmaker IntraCellular. This acquisition will allow the company access to ...

and Johnson & Johnson Vision, to name a few. On February 3, Vamil Divan, an analyst at Guggenheim, raised his price target on JNJ from $162 to $166, keeping a neutral rating on the stock.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other ...

Johnson & Johnson JNJ decided to discontinue the Phase ... Despite the above setback, J&J still maintained its vision to become the #1 neuroscience company by 2030 and also reiterated its ...

In addition to this, Johnson & Johnson’s medical device division offers solutions and operational equipment for orthopedics, advanced surgical procedures, and vision care. Bringing in $88.82 ...